Increasing incidences of syphilis around the world are expected to fuel the growth of the Treponema palladium tests market growth. According to the latest study by Persistent Market Research, the Treponema palladium tests market is expected to be valued at US$ 225 million at the end of 2026 while growing at a CAGR of 5.7 percent through 2026. The growth of the market is underpinned by the availability of an assortment of Treponema palladium tests which vary in affordability and accessibility. Syphilis diagnosis requires a patient to go through two sets of medical examinations namely Treponemal and non-Treponemal. Europe is expected to remain the largest market for Treponema palladium tests owing to the growing prevalence of syphilis in the region.
Treponema Palladium Tests Market Dynamics and Analysis
Recent studies have suggested a substantial uptick in the number of people suffering from sexually transmitted diseases. Amongst them, the occurrence of syphilis in the global population registered an increase of 18 percent during the 2015-2016 period. Centers for Disease Prevention and Control divulged that the number of people suffering from syphilis in the US has increased ever since 2001. CDC revealed that the number of incidences increased from 2.1 cases per 100,000 people to 8.7 cases per 100,000 people in 2016. As the prevalence of syphilis around the world is on the rise the demand for Treponema palladium tests is increasing which is, in turn, bolstering the growth of the Treponema palladium tests market.
Request For Report Sample@ https://www.persistencemarketresearch.com/samples/27088
Moreover, the availability of multitude Treponema diagnostics options is also fueling the growth of the market. The first diagnostic tests prescribed for syphilis detection include PCR based tests and dark-field microscopy. The non-Treponemal diagnostic procedures are inexpensive, rapid, and easy to perform while Treponemal diagnostic procedures are harder to perform and cost more than their non-Treponemal counterparts. While non-Treponemal diagnostics are used to monitor the status of the infection, Treponemal diagnostics are done to confirm the presence of infections. Treponemal tests are qualitative in nature and remain positive during the course of the treatment. On the other hand, non-Treponemal tests can be both quantitative and qualitative. The factors are expected to bolster the growth of the Treponema palladium tests market.
However, Treponema palladium tests market growth remains stunted due to limited penetration in regions with high disease burden. A report by WHO revealed that the occurrence of syphilis is highest in the African population. Despite the high prevalence of syphilis in the region, the treatment rate is low. Another report by the Makerere College of Health Sciences, Uganda divulged that over 535,000 infected with syphilis get pregnant each year while approximately 17% of pregnant women get infected by syphilis each year. Despite the low cost of non-Treponemal diagnostic procedures their availability is limited in low-income economies. Low awareness coupled with orthodox social stigma regarding sexually transmitted diseases, and the high cost of Treponema diagnostics are some of the vital reasons that are restraining the growth of the Treponema palladium tests market.
Request For Report Table of Content (TOC)@ https://www.persistencemarketresearch.com/methodology/27088
Segmental Analysis of the Treponema Palladium Tests Market
The report provides a detailed analysis of the Treponema palladium tests market on the basis of service providers and test types. On the basis of test types, the Treponema palladium tests market is divided into non-Treponemal and Treponemal tests. Out of the two test types, the non-Treponemal diagnostics segment is estimated to hold the largest share of the market. On the basis of service providers, the Treponema palladium tests market is divided into specialty clinics, hospitals, ambulatory surgical centers, academic and research institutes, and diagnostic laboratories. Hospitals emerged as the leading service providers of Treponema palladium tests in 2017.